Company:  AERIE PHARMACEUTICALS INC (AERI)
Form Type:  SC 13G/A
Filing Date:  2/16/2021 
CIK:  0001337553 
Address:  4301 EMPEROR BOULEVARD
SUITE 400
 
City, State, Zip:  DURHAM, North Carolina 27703 
Telephone:  (919) 237-5300 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$17.41  
Change: 
-0.46 (-2.57%)  
Trade Time: 
May 14  
Market Cap: 
$816.41M
Trade AERI now with 

© 2021  
Description of Business
We are an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Our strategy is to successfully commercialize our U.S. Food and Drug Administration ("FDA") approved glaucoma franchise products, Rhopressa® (netarsudil ophthalmic solution) 0.02% ("Rhopressa®") and Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% ("Rocklatan®") in the United States. Both Rhopressa® and Rocklatan® are being sold to national and regional U.S. pharmaceutical distributors, and patients have access to them through pharmacies across the United States. We have obtained formulary coverage for Rhopressa® and Rocklatan® for the majority of lives covered under commercial plans and Medicare Part D plans.
Register and access this filing in:     
  FORM SC 13G/A